blood test
-
April 28, 2021
How Can Detection of Tumor DNA in the Blood Aid Advanced Cancer Treatment?
With:As a tumor grows, it may shed fragments of its DNA into the patient’s bloodstream. After treatment, if part of the tumor remains or it begins to grow again, more of this circulating tumor DNA (ctDNA) may enter the blood. That raises the possibility that detecting ctDNA could help clinicians monitor molecular or minimal residual disease—cancer that remains after treatment and cannot be detected… Read more »
-
August 15, 2020
FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung Cancer Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
Brain Tumor Liquid Biopsy Detects DNA Methylation Profiles Bookmark
George Lundberg, MDArticle from Clinical OMICs curated by Editor in Chief George Lundberg, MD, who notes:
Researchers have recently demonstrated a noninvasive way to diagnose and classify brain tumors using a blood test. This promising “liquid biopsy” method detects cell-free tumor DNA in the blood and analyzes its chemical features—specifically, its “methylation patterns”—with high sensitivity and accuracy. Such a test could help guide treatment decisions.
Go to full article published by Clinical OMICs.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 31, 2020
Blood-Based Screening Test May Aid in Detecting GI Cancers Bookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Novel, High-Accuracy Blood Test Can Screen for Multiple Cancers Bookmark
George Lundberg, MDArticle from MDLinx curated by Editor in Chief George Lundberg, MD, who notes:
Very early detection of potentially lethal cancer remains an elusive goal. Blood tests that evaluate methylation of cell-free DNA may be one strategy for earlier detection of ovarian cancer and other types of cancer. High sensitivity and specificity are crucial.
Go to full article published by MDLinx.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 22, 2018
Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test Bookmark
Emma Shtivelman, PhDExcerpt:
“New data this week has added evidence for the value of blood-based cancer testing in non-small cell lung cancer, demonstrating in a cohort of about 300 that comprehensive liquid biopsy — in this case Guardant Health’s Guardant360 test — can help identify targeted mutations in more patients than tissue sequencing.
“The study also found that patients treated on the basis of blood-based test results respond to treatment similarly to those treated based on tissue test results.”
Go to full article published by GenomeWeb on Oct 12, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 22, 2018
Study Describes Design, Validation of Foundation Medicine’s Blood-Based TMB Test Bookmark
Emma Shtivelman, PhDExcerpt from GenomeWeb:
“Researchers from Genentech, Foundation Medicine, UC Davis, and other medical centers, have published a report on the development and early validation of Foundation’s planned blood-based tumor mutational burden test.
“Appearing today in Nature Medicine, the study describes the development of the test and its characteristics, and its retrospective validation in two cohorts. Investigators demonstrated, by applying the assay to samples from two clinical trials, that blood-based TMB (bTMB) could reproducibly identify lung cancer patients who respond to immunotherapy treatment with Roche/Genentech’s atezolizumab (Tecentriq).”
Go to full article published by GenomeWeb on Aug 4, 2018 (Free registration required).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.